# Switch Maintenance in Pancreatic

> **NCT05419479** · PHASE1,PHASE2 · SUSPENDED · sponsor: **James Cleary, MD, PhD** · enrollment: 46 (estimated)

## Conditions studied

- Pancreatic Cancer
- Adenocarcinoma of the Pancreas
- Squamous Cell Carcinoma of Pancreas
- Adenosquamous Carcinoma of the Pancreas

## Interventions

- **DRUG:** ZIMBERELIMAB
- **DRUG:** DOMVANALIMAB
- **DRUG:** APX005M
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT05419479
- **Lead sponsor:** James Cleary, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-11-30
- **Primary completion:** 2027-01-31
- **Final completion:** 2028-09-30
- **Target enrollment:** 46 (ESTIMATED)
- **Why stopped:** Efficacy concerns.
- **Last updated:** 2026-02-24

## Collaborators

- Arcus Biosciences, Inc.
- Lustgarten Foundation

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05419479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05419479, "Switch Maintenance in Pancreatic". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT05419479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*